|
|
|
Hemp Extracts from CBCeuticals:
Non-Psychoactive. Efficacious. Legal. |
|
|
On an almost daily basis, a news story or online video surfaces extolling the successful use of cannabis in the treatment of a wide range of complex, therapy-resistant conditions, including epilepsy, cancer, multiple sclerosis, and arthritis. Studies are confiming the decline of opioid use and related overdose fatalities in states that have legalized medical cannabis.
To medical professionals engaged in research or seeking the most efficacious treatments for patients, it’s become clear that the potential of cannabis-derived compounds can no longer be ignored.
Today, industrial hemp derivatives are legal to process, transport, possess, and consume in all 50 states. CBCeuticals is operating its farm under Oregon's state sactioning program, enabling the company to grow its crops in a manner compliant with state regulations.
|
|
|
|
|
|
|
|
|
|
|
Potential Applications for CBD:
Over 20,000 and growing. |
|
|
CBD (cannabidiol, the main non-psychoactive ingredient in cannabis) has been receiving significant media attention of late, largely due to viral videos demonstrating its ability to rapidly reduce seizure episodes and temors in patients affected by Dravet's Syndrome, MS, and epilepsy – without the high associated with THC.
CBD is showing promise in the treatment of various conditions, including: |
|
|
|
|
|
|
Breast Cancer |
|
|
| A paper by the American Association for Cancer Reseach confirms that CBD inflicts breast cancer cell death (aptosis). |
|
|
|
READ MORE
|
|
|
|
|
|
|
Epilepsy |
|
|
|
The International League Against Epilepsy has confirmed that CBD is efficacious against treatment-resistent forms of epilepsy. |
|
|
|
READ MORE
|
|
|
|
|
|
|
Parkinson's Disease |
|
|
| CBD has demonstrated the ability to improve the quality of life of those suffering from Parkinson's Disease. |
|
|
|
READ MORE
|
|
|
|
|
|
|
Pain Management |
|
|
|
CBD analgesics are offering an effective alternative to conventional pain management medications. |
|
|
|
READ MORE
|
|
|
|
|
|
|
|
|
|
|
|
|
